Key Inclusion Criteria:

          -  18 years of age or older

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Histologically or cytologically documented, incurable or metastatic solid tumor that
             is advanced (non-resectable) or recurrent and progressing since the last anti-tumor
             therapy and for which no recognized standard therapy exists

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or
             per other criteria best suited for the specific tumor type being evaluated

          -  Willing to complete all scheduled visits and assessments at the institution
             administering therapy

        Key Exclusion Criteria:

          -  Treatment with any local or systemic antineoplastic therapy (including chemotherapy,
             hormonal therapy, or radiation) within 3 weeks prior to first dose of AMV564

          -  Major trauma or major surgery within 4 weeks prior to first dose of AMV564

          -  Prior treatment with chimeric antigen receptor (CAR) T-cell therapy or T-cell engager
             therapy

          -  Chronic use of corticosteroids in excess of 10 mg daily of prednisone or equivalent
             within 4 weeks prior to first dose of AMV564

          -  Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1
             except for alopecia

          -  Known, central nervous system (CNS) disease involvement, or prior history of National
             Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Grade ≥ 3
             drug-related CNS toxicity